SMA (Spinal Muscular Atrophy)

This is a condition where the nerves that control your muscles start to break down over time. This causes muscles to become weak and waste away. It's usually inherited, meaning it runs in families, and it affects people of all ages, though it's often diagnosed in children.

Condition

What people with SMA (Spinal Muscular Atrophy) report

Every report comes from a Lived member, sent anonymously.

Have you had Noninvasive Ventilation for SMA (Spinal Muscular Atrophy)?

NameHow it went

About SMA (Spinal Muscular Atrophy)

What It Is

Spinal muscular atrophy (SMA) is an inherited disease in which motor neurons, the nerve cells in the spinal cord and lower brain that send movement signals to muscles, are gradually lost. Without those signals, muscles weaken and shrink. Weakness is usually greatest in the muscles closest to the trunk, such as the hips, thighs and shoulders, and it can also affect the muscles used for breathing, coughing and swallowing. SMA does not affect intelligence. SMA ranges widely in severity. It is traditionally grouped by when symptoms start and the highest movement a person reaches. Type 1, the most common, appears before 6 months of age, and babies usually cannot sit without help. Type 2 is noticed between 6 and 18 months; children can sit but not walk on their own. Type 3 begins after 18 months; people walk but may struggle with stairs, running or rising from a chair. Type 4 begins in adulthood and causes milder leg weakness. Types 0 (before birth) and 4 are rare. Newer treatments are changing how these types play out, so doctors increasingly describe SMA by genetic results and actual abilities as well.

Causes & Risk Factors

Most SMA is caused by changes in both copies of a gene called SMN1. This gene makes the survival motor neuron (SMN) protein that motor neurons need to stay healthy. A neighboring backup gene, SMN2, makes a small amount of working SMN protein. The number of SMN2 copies a person has varies, and more copies generally mean milder disease that starts later. That is why SMN2 copy number helps predict severity, especially in babies found through screening. SMN1-related SMA is recessive: a child is affected when both parents pass on a changed copy. Carriers, who have one changed copy, have no symptoms and often do not know. When both parents are carriers, each pregnancy has a 1 in 4 chance of a child with SMA. Overall, SMA affects roughly 1 in 8,000 to 11,000 babies. Carrier testing is available for relatives and for people planning a pregnancy. A few rarer forms of SMA, including some that mainly affect the hands and feet, come from changes in other genes and can be inherited differently.

How It's Diagnosed

Many babies are now identified through newborn screening, a heel-prick blood test that many programs use to check for missing SMN1 before any symptoms appear. A normal screen does not rule out SMA if weakness appears later, because it misses some SMN1 changes and the rarer forms. Otherwise, a clinician may suspect SMA when a baby is floppy, is missing motor milestones such as holding up the head or sitting, or when an older child or adult develops weakness in the hips and shoulders. A genetic blood test confirms the diagnosis by showing that both copies of SMN1 are missing or altered, and it detects at least 95% of types 1 through 3. The same testing counts SMN2 copies, which helps estimate severity and guide treatment timing. If genetic results are normal or the picture is unusual, tests of nerve and muscle electrical activity (electromyography and nerve conduction studies) or occasionally a muscle biopsy help identify other conditions or rarer forms of SMA. Families with a known history can have testing during pregnancy through chorionic villus sampling or amniocentesis (sampling placental tissue, or fluid around the baby, to test the baby's genes).

Treatment Options

There is no cure for SMA, but treatments that raise SMN protein can preserve motor neurons, improve strength and survival, and help many people sit, stand or walk who otherwise would not. They cannot restore motor neurons that are already gone, so starting early, ideally before symptoms in babies found by screening, gives the greatest benefit. These medicines treat SMA caused by SMN1 changes; they do not treat the rarer forms caused by other genes, whose care is supportive and depends on the specific diagnosis. Three approved approaches differ mainly in how they are given and who can receive them: Nusinersen (Spinraza) is an injection into the fluid around the spinal cord through a lumbar puncture (spinal tap). After several starting doses, it is given every 4 months for life, with blood and urine tests before each dose to check platelets, clotting and kidney function. It is approved for children and adults. Risdiplam (Evrysdi) is a liquid or tablet taken by mouth once a day, approved for children and adults. It avoids repeated spinal injections, but it may harm a developing pregnancy and may reduce male fertility, so contraception and family planning are part of the conversation. Gene therapy with onasemnogene abeparvovec delivers a working copy of the SMN1 gene in a single treatment. Zolgensma is an intravenous infusion for children under 2; Itvisma is a spinal injection for people 2 and older. Because gene therapy can cause serious liver injury, people receive steroid medicine around the treatment and liver blood tests for at least 3 months. The choice depends on age, current abilities, SMN2 copies, practical burden and access. Supportive care remains essential with any medicine: physical and occupational therapy, braces and wheelchairs to support independence, monitoring and treatment of scoliosis (sideways curving of the spine), nutrition and swallowing support (sometimes a feeding tube), and breathing support, which for many people starts with a mask ventilator during sleep.

What to Expect

The outlook depends heavily on the type and on how early treatment began. Before current treatments, many babies with type 1 died before age 2. Today, children treated early often survive longer and reach milestones once thought out of reach, though many still have some weakness. People with type 3 usually have a normal lifespan, and type 4 does not shorten life. Results vary from person to person, and long-term outcomes of the newer treatments are still being learned. SMA care is typically organized around a specialist neuromuscular team that may include a neurologist, lung specialist, physical therapist, dietitian and orthopedic surgeon. Regular visits track strength, breathing, swallowing, weight and spine curvature so problems can be addressed before they become crises. Daily life often involves therapy routines, equipment and, for some, nighttime breathing support. Adults with SMA may find it harder to get the same coordinated care children receive, so it helps to plan the move from pediatric to adult services ahead of time.

When to Seek Help

Arrange an evaluation if a baby seems floppy, is losing or not reaching motor milestones, or if a child or adult develops unexplained weakness in the hips, thighs or shoulders. If SMA runs in your family, talk with a clinician or genetic counselor before or early in a pregnancy. For someone with SMA, contact the care team promptly about a cold, cough or fever, a weaker cough or trouble clearing mucus, new choking or difficulty feeding, weight loss, or poor sleep with disturbed breathing at night. Chest infections can become serious quickly when breathing muscles are weak. Struggling to breathe or bluish lips or face during an illness needs emergency care: call 911.

Questions to Ask Your Doctor

  1. 1.What type of SMA is this, how many SMN2 copies are there, and what does that suggest about the likely course?
  2. 2.Which treatment fits our situation best, and how will we judge whether it is working?
  3. 3.What should we watch for with breathing, swallowing and the spine, and how often should each be checked?
  4. 4.What is our plan if a cold or chest infection starts, including what to do at home and when to call?
  5. 5.Should other family members have carrier testing, and what are the options for a future pregnancy?

Last reviewed • Oct 2026

Educational content, not medical advice.